PDS Biotechnology(PDSB)2024-11-14 13:05Financial Performance - Reported net loss for Q3 2024 was approximately 0.29 per share, compared to a net loss of 0.35 per share in Q3 2023[7]. - General and administrative expenses decreased to approximately 4.1 million in Q3 2023, mainly due to lower personnel costs[9]. - Total operating expenses decreased to approximately 10.5 million in Q3 2023[10]. - The company reported a decrease in total stockholders' equity to approximately 26.1 million at the end of 2023[15]. - Long-term debt decreased to approximately 19.5 million at the end of 2023[15]. Research and Development - Research and development expenses increased to approximately 6.4 million in Q3 2023, primarily due to higher manufacturing expenses[8]. - The updated VERSATILE-003 trial design will include approximately 350 patients and aims for earlier interim readouts and reduced execution costs[4]. - The IMMUNOCERV Phase 2 trial data presented at ASTRO showed promising clinical activity and a compelling safety profile for Versamune® HPV[3]. Regulatory and Future Plans - The company plans to submit an updated IND application to the FDA, expecting clearance by mid-December 2024[2]. - Cash and cash equivalents as of September 30, 2024, totaled approximately 56.6 million at the end of 2023[15].